AU2013268725B2 - Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent - Google Patents

Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent Download PDF

Info

Publication number
AU2013268725B2
AU2013268725B2 AU2013268725A AU2013268725A AU2013268725B2 AU 2013268725 B2 AU2013268725 B2 AU 2013268725B2 AU 2013268725 A AU2013268725 A AU 2013268725A AU 2013268725 A AU2013268725 A AU 2013268725A AU 2013268725 B2 AU2013268725 B2 AU 2013268725B2
Authority
AU
Australia
Prior art keywords
thrombomodulin
amino acid
medicament according
administration
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013268725A
Other languages
English (en)
Other versions
AU2013268725A1 (en
Inventor
Atsufumi Kawabata
Hideaki Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Kindai University
Original Assignee
Asahi Kasei Pharma Corp
Kindai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp, Kindai University filed Critical Asahi Kasei Pharma Corp
Publication of AU2013268725A1 publication Critical patent/AU2013268725A1/en
Application granted granted Critical
Publication of AU2013268725B2 publication Critical patent/AU2013268725B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013268725A 2012-05-31 2013-05-17 Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent Active AU2013268725B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31
JP2012-125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
AU2013268725A1 AU2013268725A1 (en) 2014-12-18
AU2013268725B2 true AU2013268725B2 (en) 2017-02-16

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013268725A Active AU2013268725B2 (en) 2012-05-31 2013-05-17 Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent

Country Status (20)

Country Link
US (1) US10709767B2 (enExample)
EP (1) EP2857037B1 (enExample)
JP (3) JP6124417B2 (enExample)
KR (1) KR101672114B1 (enExample)
CN (1) CN104394885B (enExample)
AU (1) AU2013268725B2 (enExample)
BR (1) BR112014028852A2 (enExample)
CA (1) CA2875069C (enExample)
DK (1) DK2857037T3 (enExample)
ES (1) ES2743767T3 (enExample)
HU (1) HUE045997T2 (enExample)
IL (1) IL235984B (enExample)
IN (1) IN2014DN10075A (enExample)
MX (1) MX364934B (enExample)
NZ (1) NZ702242A (enExample)
PL (1) PL2857037T3 (enExample)
PT (1) PT2857037T (enExample)
RU (1) RU2595857C2 (enExample)
WO (1) WO2013179910A1 (enExample)
ZA (1) ZA201408769B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2857037T3 (da) * 2012-05-31 2019-07-22 Univ Kinki Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
AU2018245892B2 (en) * 2017-03-31 2022-02-24 Toray Industries, Inc. Therapeutic or prophylactic agent for peripheral neuropathies
US11628147B2 (en) 2017-12-19 2023-04-18 Synergia Life Sciences Pvt. Ltd. Vitamin K2 compositions for the treatment of drug induced neuropathy
CA3112679A1 (en) 2018-09-28 2020-04-02 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли
CN116897010A (zh) * 2021-02-26 2023-10-17 韦博辛斯动力公司 用于预测化疗引起的神经病变的生物标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034060A (en) * 1987-01-08 2000-03-07 Asahi Kasei Kogyo Kabushiki Kaisha Peptide having an ability to promote the activation of protein C by thrombin
WO2010006634A1 (en) * 2008-07-16 2010-01-21 Paion Deutschland Gmbh Prevention and treatment of radiation injury
US20110212900A1 (en) * 2010-02-26 2011-09-01 National University Corporation Kochi University Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
CA2065409C (en) 1990-06-27 2002-05-14 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
EP0685994B1 (en) 1993-02-25 2007-03-21 Abbott Laboratories Multipurpose reagent system for rapid lysis of whole blood samples
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
EP0763360B1 (en) 1994-04-20 2005-02-16 Asahi Kasei Pharma Corporation Use of thrombomodulin for treating liver injury
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
CA2213000A1 (en) 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
WO2001072328A2 (en) 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
RU2007130722A (ru) * 2005-02-16 2009-03-27 Вайет (Us) Способы и устройства для диагностики, прогнозирования и выбора лечения лейкоза
WO2009012221A1 (en) 2007-07-13 2009-01-22 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
RU2537226C2 (ru) 2008-02-18 2014-12-27 Лабораторьос Дель Др. Эстеве, С.А. Применение соединений, связывающихся с лигандами сигма-рецептора, для лечения развития невропатической боли вследствие химиотерапии
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
DK2857037T3 (da) 2012-05-31 2019-07-22 Univ Kinki Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034060A (en) * 1987-01-08 2000-03-07 Asahi Kasei Kogyo Kabushiki Kaisha Peptide having an ability to promote the activation of protein C by thrombin
WO2010006634A1 (en) * 2008-07-16 2010-01-21 Paion Deutschland Gmbh Prevention and treatment of radiation injury
US20110212900A1 (en) * 2010-02-26 2011-09-01 National University Corporation Kochi University Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation

Also Published As

Publication number Publication date
JP2018095652A (ja) 2018-06-21
ZA201408769B (en) 2015-12-23
CA2875069A1 (en) 2013-12-05
PT2857037T (pt) 2019-07-19
JP2017141268A (ja) 2017-08-17
CN104394885B (zh) 2017-06-30
JP6279788B2 (ja) 2018-02-14
US20150148296A1 (en) 2015-05-28
IN2014DN10075A (enExample) 2015-08-21
JP6124417B2 (ja) 2017-05-10
WO2013179910A1 (ja) 2013-12-05
EP2857037A1 (en) 2015-04-08
IL235984B (en) 2019-09-26
RU2014148171A (ru) 2016-07-20
EP2857037B1 (en) 2019-06-26
JP6427284B2 (ja) 2018-11-21
MX364934B (es) 2019-03-28
ES2743767T3 (es) 2020-02-20
DK2857037T3 (da) 2019-07-22
BR112014028852A2 (pt) 2018-04-24
US10709767B2 (en) 2020-07-14
CN104394885A (zh) 2015-03-04
JPWO2013179910A1 (ja) 2016-01-18
KR20150004855A (ko) 2015-01-13
EP2857037A4 (en) 2016-04-06
PL2857037T3 (pl) 2019-12-31
KR101672114B1 (ko) 2016-11-02
HK1203846A1 (en) 2015-11-06
IL235984A0 (en) 2015-01-29
RU2595857C2 (ru) 2016-08-27
NZ702242A (en) 2016-03-31
AU2013268725A1 (en) 2014-12-18
MX2014014505A (es) 2015-06-02
HUE045997T2 (hu) 2020-01-28
CA2875069C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
CA2875069C (en) Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
TWI579299B (zh) 去整合蛋白變異體及其醫藥用途
EP3723791B1 (en) Recombinant igg fc multimers for the treatment of neuromyelitis optica
JP7245844B2 (ja) 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
HK1203846B (en) Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug
HK40037563B (en) Recombinant igg fc multimers for the treatment of neuromyelitis optica
HK40037563A (en) Recombinant igg fc multimers for the treatment of neuromyelitis optica

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ AGENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIC PAIN CAUSED BY ANTICANCER AGENT

FGA Letters patent sealed or granted (standard patent)